Daiichi Sankyo Absorbs 130 Medical Representatives From Merck KGaA
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo announced July 16 that its German subsidiary agreed to take in 130 medical representatives from Merck KGaA. Since Merck KGaA's decision not to continue marketing activities to medical facilities for drugs whose patents have expired, Daiichi Sankyo decided to take half of the medical representatives and merge them into its own sales force. Currently, 70 percent of Daiichi Sankyo's sales come from the Japanese domestic market. The company hopes to reach 70 percent of sales from the overseas market by 2015. The company is rapidly expanding business in Europe, and in Germany, it has acquired bio-pharmaceutical company Morphosys and antibody maker U3 Pharma. (Click here for more - Japanese language) "In Germany Daiichi Sankyo Takes In 130 Medical Representatives From Merck" - NNA News (7/18/08)